Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Gene therapy for adenosine deaminase–deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans

Blood (2012) 120 (18): 3635–3646.

https://doi.org/10.1182/blood-2012-02-400937

Published: 2012

Includes: Supplemental data

Journal Articles

Analysis of T-cell repertoire diversity in Wiskott-Aldrich syndrome

Taizo Wada, Shepherd H. Schurman, Elizabeth K. Garabedian, Akihiro Yachie, Fabio Candotti

Blood (2005) 106 (12): 3895–3897.

https://doi.org/10.1182/blood-2005-06-2336

Published: 2005

Journal Articles

Analysis of Retroviral Vector Insertion Sites after T-Cell Directed Gene Therapy.

Akihiro Konno, MD, PhD, G. Jayashree Jagadeesh, BS, Daniele Moratto, PhD, Marita Bosticardo, PhD, Ingeborg Holt, PhD, Linda M. Muul, PhD, Shepherd H. Schurman, MD, Tyra Wolfsberg, PhD, Fabio Candotti, MD

Blood (2004) 104 (11): 289.

https://doi.org/10.1182/blood.V104.11.289.289

Published: 2004

Journal Articles

Multiple patients with revertant mosaicism in a single Wiskott-Aldrich syndrome family

Taizo Wada, Shepherd H. Schurman, G. Jayashree Jagadeesh, Elizabeth K. Garabedian, David L. Nelson, Fabio Candotti

Blood (2004) 104 (5): 1270–1272.

https://doi.org/10.1182/blood-2004-03-0846

Published: 2004

Journal Articles

Differential contribution of Wiskott-Aldrich syndrome protein to selective advantage in T- and B-cell lineages

Akihiro Konno, Taizo Wada, Shepherd H. Schurman, Elizabeth K. Garabedian, Martha Kirby, Stacie M. Anderson, Fabio Candotti

Blood (2004) 103 (2): 676–678.

https://doi.org/10.1182/blood-2003-05-1739

Published: 2004

Journal Articles

Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial

Linda Mesler Muul, Laura M. Tuschong, Sherry Lau Soenen, G. Jayashree Jagadeesh, W. Jay Ramsey, Zhifeng Long, Charles S. Carter, Elizabeth K. Garabedian, Melinna Alleyne, Margaret Brown, Wendy Bernstein, Shepherd H. Schurman, Thomas A. Fleisher, Susan F. Leitman, Cynthia E. Dunbar, R. Michael Blaese, Fabio Candotti

Blood (2003) 101 (7): 2563–2569.

https://doi.org/10.1182/blood-2002-09-2800

Published: 2003

NARROW

Gene therapy for adenosine deaminase–deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans

Analysis of T-cell repertoire diversity in Wiskott-Aldrich syndrome

Analysis of Retroviral Vector Insertion Sites after T-Cell Directed Gene Therapy.

Multiple patients with revertant mosaicism in a single Wiskott-Aldrich syndrome family

Differential contribution of Wiskott-Aldrich syndrome protein to selective advantage in T- and B-cell lineages

Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial

Email alerts

ASH Publications

American Society of Hematology

Gene therapy for adenosine deaminase–deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans

Analysis of T-cell repertoire diversity in Wiskott-Aldrich syndrome

Analysis of Retroviral Vector Insertion Sites after T-Cell Directed Gene Therapy.

Multiple patients with revertant mosaicism in a single Wiskott-Aldrich syndrome family

Differential contribution of Wiskott-Aldrich syndrome protein to selective advantage in T- and B-cell lineages

Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only